Protein Science, Vol 7, Issue 11 2314-2323, Copyright © 1998 by Cold Spring Harbor Laboratory Press

ARTICLE

Toward a universal inhibitor of retroviral proteases: Comparative analysis of the interactions of LP-130 complexed with proteases from HIV-1, FIV, and EIAV

J. KERVINEN, J. LUBKOWSKI, A. ZDANOV, D. BHATT, B. M. DUNN, K. Y. HUI, D. J. POWELL, J. KAY, A. WLODAWER and A. GUSTCHINA
Macromolecular Structure Laboratory, ABL-Basic Research Program, NCI-Frederick Cancer Research and Development Center, Frederick, Maryland 21702

One of the major problems encountered in antiviral therapy against AIDS is the emergence of viral variants that exhibit drug resistance. The sequences of proteases (PRs) from related retroviruses sometimes include, at structurally equivalent positions, amino acids identical to those found in drug-resistant forms of HIV-1 PR. The statine-based inhibitor LP-130 was found to be a universal, nanomolar-range inhibitor against all tested retroviral PRs. We solved the crystal structures of LP-130 in complex with retroviral PRs from HIV-1, feline immunodeficiency virus, and equine infectious anemia virus and compared the structures to determine the differences in the interactions between the inhibitor and the active-site residues of the enzymes. This comparison shows an extraordinary similarity in the binding modes of the inhibitor molecules. The only exceptions are the different conformations of naphthylalanine side chains at the P3/P3' positions, which might be responsible for the variation in the K(i) values. These findings indicate that successful inhibition of different retroviral PRs by LP-130 is achieved because this compound can be accommodated without serious conformational differences, despite the variations in the type of residues forming the active-site region. Although strong, specific interactions between the ligand and the enzyme might improve the potency of the inhibitor, the absence of such interactions seems to favor the universality of the compound. Hence, the ability of potential anti-AIDS drugs to inhibit multiple retroviral PRs might indicate their likelihood of not eliciting drug resistance. These studies may also contribute to the development of a small-animal model for preclinical testing of antiviral compounds.
CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				P. Bagossi, T. Sperka, A. Feher, J. Kadas, G. Zahuczky, G. Miklossy, P. Boross, and J. Tozser Amino Acid Preferences for a Critical Substrate Binding Subsite of Retroviral Proteases in Type 1 Cleavage Sites J. Virol., April 1, 2005; 79(7): 4213 - 4218. [Abstract] [Full Text] [PDF]

				A. Fernandez, K. Rogale, R. Scott, and H. A. Scheraga Inhibitor design by wrapping packing defects in HIV-1 proteins PNAS, August 10, 2004; 101(32): 11640 - 11645. [Abstract] [Full Text] [PDF]

				C. Voisset, R. E. Myers, A. Carne, P. Kellam, and D. J. Griffiths Rabbit endogenous retrovirus-H encodes a functional protease J. Gen. Virol., January 1, 2003; 84(1): 215 - 225. [Abstract] [Full Text] [PDF]